Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
Trial record 6 of 77 for:    611

Feasibility Study of Low Level Light Therapy for Prevention of Oropharyngeal Mucositis in Pediatric Transplants Patients

This study has been completed.
Information provided by (Responsible Party):
Nathaniel S. Treister, DMD, DMSc, Dana-Farber Cancer Institute Identifier:
First received: April 9, 2014
Last updated: January 25, 2017
Last verified: January 2017
Oral mucositis (OM) is a painful and potentially debilitating acute toxicity that frequently affects children undergoing hematopoietic cell transplantation (HCT). As a result of intensive conditioning with chemotherapy with or without total body irradiation, and in the case of allogeneic HCT, graft-versus-host disease (GVHD) prophylaxis, patients are at risk for developing diffuse ulcerations of the oral and esophageal mucosa that result in pain and suffering, increased utilization of opioid analgesics, and the need for intravenous or total parenteral nutritional support. Patients universally report OM as being the worst aspect of the HCT experience.A novel approach has been the use of larger light-emitting diode arrays to treat the at risk tissues from an extraoral approach, enabling exposure of the oral, oropharyngeal, and esophageal mucosa while avoiding the need for intraoral manipulation, and requiring only minimal patient cooperation. In this research study, the investigators are assessing the feasibility of providing extraorally delivered low level light therapy (LLLT) for the prevention of OM in children undergoing myeloablative HCT.

Condition Intervention
Oropharyngeal Mucositis
Myeloablative Hematopoietic Cell Transplantation
Low Level Light Therapy
Device: Low Level Light Therapy

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: No masking
Primary Purpose: Device Feasibility
Official Title: Feasibility Study Evaluating Extraorally Delivered Low Level Light Therapy (LLLT) for the Prevention of Oropharyngeal Mucositis in Pediatric Patients Undergoing Myeloablative Hematopoietic Cell Transplantation

Further study details as provided by Dana-Farber Cancer Institute:

Primary Outcome Measures:
  • The ability to maneuver and provide a new treatment for mucositis using (extraoral) LLLT [ Time Frame: 20 Days ]

    Several measures will be collected to evaluate the overall feasibility of providing daily extraoral LLLT for children undergoing HSCT including:

    • Accessibility and maneuverability of the LLLT device (transportation from storage site to hospital room, device weight)
    • Administration of LLLT (device settings, positioning of device, delivery of therapy)
    • Patient tolerability (level of comfort during treatments, compliance with daily therapy
    • Proportion of days with therapy administered, as evidence by data submitted (goal is ≥75%)
    • Ability to enroll at least 5 patients within the first 3 months (this pertains to the feasibility of study conduct, and not to the feasibility of the therapeutic approach)

Secondary Outcome Measures:
  • Patient compliance with completing questionnaires [ Time Frame: 2 Years ]
    To address secondary the investigators, will calculate the following proportion: (number of times patients refused to complete one or both questionnaires) / (number of questionnaire completion timepoints), and place a 95% confidence interval on the proportion.

  • WHO Oral Toxicity Scale/ChIMES Instrument [ Time Frame: 2 Years ]
    To address secondary aim, the investigator, will analyze the data from the WHO Oral Toxicity Scale and the ChIMES instrument using the analytic methods specifically prescribed for these standardized instruments.

  • Toxicity measured using CTC Version [ Time Frame: 2 Years ]
  • Dose-limiting toxicity [ Time Frame: 2 Years ]

Enrollment: 13
Study Start Date: April 2014
Study Completion Date: April 2016
Primary Completion Date: November 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Low Level Light Therapy (LLLT)
  • LLLT: The LLLT device will be positioned next to the face and neck for a total of 6 exposures: Right face, Midline face, Left face, Left neck, Midline neck, Right neck
  • Dose per anatomic site 50mW/cm2, 60 sec = 3.0J/cm2
  • Route: Extraoral
  • Total Treatment Time (all sites): 6 min
  • Schedule: Participants will be treated daily (including weekends and holidays) beginning on the first day of HCT conditioning and continuing through day +20 or hospital discharge if prior to day +20.
  • Evaluation: Participants will undergo formal mucositis and toxicity assessments at baseline and daily from day -1 through day +20, with a final assessment on the last day of treatment.
Device: Low Level Light Therapy
Other Name: THOR Model LX2M (THOR Photomedicine Ltd, Chesham, UK)

Detailed Description:

This is an open label, single treatment arm clinical pilot study. The study is targeted to enroll twelve evaluable patients



  • Determine the feasibility of providing extraoral LLLT for prevention of OM in pediatric patients undergoing HCT


  • Determine the feasibility of collecting data using the WHO Oral Toxicity Scale and ChIMES in pediatric patients undergoing myeloablative HCT who are treated with extraoral LLLT for prevention of OM
  • Evaluate the safety and tolerability of extraoral LLLT for prevention of OM in pediatric patients undergoing myeloablative HCT

Ages Eligible for Study:   4 Years to 25 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Scheduled to undergo myeloablative conditioning followed by autologous or allogeneic hematopoietic cell transplantation at Boston Children's Hospital.
  • 4 years of age to 25 years of age.
  • WHO Oral Toxicity score of 0 at baseline evaluation (first day of conditioning).
  • Ability to understand and the willingness to sign a written informed consent document (for patients under the age of 18 this applies to parent/guardian)
  • Ability to understand and/or the willingness of their parent or legally authorized representative to sign a written informed consent document.

Exclusion Criteria:

  • Treatment with oral LLLT within 4 weeks of HCT.
  • Participants may not be receiving any other agents intended for the prevention/management of mucositis (including palifermin and ice chips/cryotherapy).
  • WHO ≥1 at baseline evaluation.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT02119897

United States, Massachusetts
Boston Children's Hospital
Boston, Massachusetts, United States, 02115
Dana Farber Cancer Institute
Boston, Massachusetts, United States, 02115
Sponsors and Collaborators
Dana-Farber Cancer Institute
Principal Investigator: Nathaniel Treister, DMD,DMSc Brigham and Women's Hospital
  More Information

Responsible Party: Nathaniel S. Treister, DMD, DMSc, Principal Investigator, Dana-Farber Cancer Institute Identifier: NCT02119897     History of Changes
Other Study ID Numbers: 13-611
Study First Received: April 9, 2014
Last Updated: January 25, 2017
Individual Participant Data  
Plan to Share IPD: No

Keywords provided by Dana-Farber Cancer Institute:
Oropharyngeal Mucositis
Myeloablative Hematopoietic Cell Transplantation
Low Level Light Therapy

Additional relevant MeSH terms:
Gastrointestinal Diseases
Digestive System Diseases
Mouth Diseases
Stomatognathic Diseases processed this record on April 26, 2017